¹⁷⁷Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer

Table 1

Patient characteristics before ¹⁷⁷Lu-iPSMA treatments.

Site of metastases	Patients (18 treatments)
	N	%
Bone	6	60
Lymph nodes	10	100
Liver	4	40
Lung	1	10
Prior therapies
Radical prostectomy	8	80
Radiation therapy (prostate region)	8	80
Docetaxel	7	70
Cabazitaxel, abiraterone, and/or enzalutamide	7	70
Radium-223	1	10
Radiation therapy to bone	2	20